Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 4, 2010, Pages 256-261

  Llopis Salvia, Pilar ^a   Sarrio Montes, Gema ^a   Garcia Llopis, Paula ^a   Bargues Ruiz, Adria ^a  

^a HOSPITAL DE LA RIBERA   (Spain)

Author keywords

adverse drug reaction; antineoplastic chemotherapy; dose intensity

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COLORECTAL CANCER; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HEARTBURN; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NEUTROPENIA; OUTPATIENT DEPARTMENT; PARESTHESIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

AGED; AGING; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 78650444858     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209355848     Document Type: Article

References (14)

1. Hryniuk W., Levine MN Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986 ; 4: 1162-70.
2. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study community practices. J Clin Oncol 2003 ; 21: 4524-31.
3. Ladewinski LA, Belknap SM, Nebeker JR, Sartor O., Lyons A., Kuzel TC et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003 ; 21: 3589-66.
4. Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
5. Poole SG, Dooley MJ Establishing a baseline incidence of adverse drug reactions in hospitalised oncology patients. J Oncol Pharm Practice 2000 ; 6: 55-9.
6. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R., Montello MJ et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003 ; 21: 1383-9.
7. Yancik R., Ries LAG. Cancer in older persons: an international issue in an ageing world. Semin Oncol 2004 ; 31: 128-36.
8. Tam JT, Payne J., Teplitzky B., Ershler W., Balducci L. Perceptions of clinical trial participation between community practitioners and older cancer patients. J Clin Oncol 2004 ; 22 (14). 8260.
9. Lichtman SM Chemotherapy in the elderly. Semin Oncol 2004 ; 31: 160-74.
10. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 DCTD, NCI, NHI, DHHS. March 31, 2003. Available at: http://ctep.cancer.gov (accessed 13 November 2009 ).
11. Bloechl-Daum B., Deuson RR, Mavros P., Hansen M., Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006 ; 24: 4472-8.
12. Bonadonna G., Valagussa O., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophospamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up N Eng Med J 1995 ; 332: 901-6.
13. De Maio E., Gravina A., Pacilio C., Amabile G., Labonia V., Landi G. et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Med Res Methodol 2005 ; 5: 30.
14. Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 2007 ; 43: 2235-41.